CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals is set to present promising clinical data on its anti-ROR1 ADC, CS5001, for lymphoma at the upcoming American Society of Hematology Annual Meeting. This innovative drug has shown substantial anti-tumor activity, achieving an objective response rate of 43.5% in advanced B-cell lymphoma cases. As CStone continues to expand its global Phase I trial, investors and stakeholders should keep an eye on this potential breakthrough in cancer treatment.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- No Resolution Between Paramount Global (NASDAQ:PARA) and Nielsen
- Ford (NYSE:F) Enters Mustang Mach-E in Road Rally
- Concerns Growing Over Intel (NASDAQ:INTC) Battlemage Line
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
